Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Alpha-Synuclein (alphaSyn or SNCA) Pipeline Review, H1 2016 - 12 Companies/Institutions & 29 Molecules - Research and Markets

Research and Markets
Posted on: 31 Aug 16

Research and Markets has announced the addition of the "Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016" report to their offering.

Alpha-Synuclein (alphaSyn or SNCA) Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson's. In Parkinson's it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.

Alpha-Synuclein (alphaSyn or SNCA) pipeline Target constitutes close to 29 molecules, out of which approximately 24 molecules are developed by Companies and the remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 13 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules.

The report "Alpha-Synuclein - Pipeline Review, H1 2016" outlays comprehensive information on the Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Alpha-Synuclein Overview
  3. Therapeutics Development
  4. Pipeline Products for Alpha-Synuclein - Overview
  5. Pipeline Products for Alpha-Synuclein - Comparative Analysis
  6. Alpha-Synuclein - Therapeutics under Development by Companies
  7. Alpha-Synuclein - Therapeutics under Investigation by Universities/Institutes
  8. Alpha-Synuclein Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Alpha-Synuclein - Products under Development by Companies
  13. Alpha-Synuclein - Products under Investigation by Universities/Institutes
  14. Alpha-Synuclein - Companies Involved in Therapeutics Development
  • AC Immune SA
  • AFFiRiS AG
  • BioArctic Neuroscience AB
  • Biogen, Inc.
  • NeuroPhage Pharmaceuticals, Inc.
  • Neuropore Therapies, Inc.
  • nLife Therapeutics, S.L.
  • Primary Peptides, Inc.
  • Prothena Corporation Plc
  • QR Pharma, Inc.
  • reMYND NV
  • Synovo GmbH

For more information about this report visit

Related Topics: Central Nervous System Drugs

View source version on

Business Wire

Last updated on: 31/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.